Xuefu Zhuyu Oral Liquid Trial: Efficacy and Safety Data for Stable Angina

148 patient records from a multicenter randomized controlled trial evaluating Xuefu Zhuyu oral liquid as adjunctive therapy for stable angina. The trial was conducted across six hospitals in China between June 2020 and June 2022, with results published by Wencong Cao. Data likely includes primary outcome measures such as pain intensity scores and rescue medication usage.

Use Cases

• Analyze the efficacy of adjunctive traditional Chinese medicine based on changes in visual analog scale pain scores.
• Compare safety profiles between treatment and placebo groups based on adverse event reporting.
• Evaluate the impact on rescue medication needs based on nitroglycerin usage rates.
• Model treatment effects over a 24-week follow-up period based on sustained outcome measurements.

Strengths

• Data originates from a rigorous multicenter, randomized, double-blind, placebo-controlled trial design.
• Results include statistically significant primary outcomes (P=0.012) and sustained effects at 24-week follow-up.
• The dataset is associated with a registered clinical trial (ChiCTR1900026899), providing traceability.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (29.9 KB), indicating limited scope and likely summary-level data.

Provenance

Source

figshare, author Wencong Cao

Collection Method

Clinical trial data collection from a randomized controlled trial.

Time Range

June 2020 to June 2022 (trial period), with an additional 12-week follow-up.

Freshness

Last updated 2026-04-29 05:54:24; freshness should be verified.

Geography

Six hospitals in China.